Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score

British Journal of Haematology

Volumn 97, Issue 1, 1997, Pages 76-85

  Hehlmann, R ^a   Ansari, H ^a   Hasford, J ^a   Heimpel, H ^a   Hossfeld, D K ^a   Kolb, H J ^a   Loffler H ^a   Pralle, H ^a   Queisser, W ^a   Reiter, A ^a   Hochhaus, A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CML; IFN ; new score; risk profiles; Sokal's index

Indexed keywords

ALPHA INTERFERON; BUSULFAN; HYDROXYUREA;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK; SURVIVAL;

EID: 8244233829     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.102652.x     Document Type: Article

References (28)

1. Alimena, G., Morra, E., Lazzarino, M., Liberati, A.M., Montefusco, E., Inverardi, D., Bernasconi, P., Mancini, M., Donti, E., Grignani, F., Bernasconi, C., Dianzani, F. & Mandelli, F. (1988) Interferon alpha-2b as therapy for Ph-positive chronic myelogenous leukemia: a study of H2 patients treated with intermittent or daily administration. Blood, 72, 642-647.
2. Allan, N.C., Richards, S.M. & Shepherd, P.C.A. (1995) UK Medical Research Council randomized, multicentre trial of interferon-αn1 for chronic myeloid leukaemia is not confined to patients with cytogenetic response: improved survival irrespective of cytogenetic response. Lancet, 345, 1392-1397.
3. Cervantes, F., Robertson, J.E., Rozman, C., Baccarani, M., Tura, S., Gomez, G.A., Braun, T.J., Clarkson, B.D. & Pereira, A. (1994) Long-term survivors in chronic granulocytic leukaemia: a study by the International CGL Prognosis Study Group/Italian Cooperative CML Study Group. British Journal of Haematology, 87, 293-300.
4. Cervantes, F. & Rozman, C. (1982) A multivariate analysis of prognostic factors in chronic myeloid leukemia. Blood, 60, 1298-1304.
5. Guilhot, F., Dreyfus, B., Brizard, A., Hure, J.L. & Tanzer, J. (1991) Cytogenetic remissions in chronic myelogenous leukemia using interferon alpha-2a and hydroxyurea with or without low-dose cytosine arabinoside. Leukemia and Lymphoma, 4, 49-55.
6. Hasford, J., Ansari, H., Pfirrmann, M., Hehlmann, R., and the German CML Study Group (1996a) Analysis and validation of prognostic factors for CML. Bone Marrow Transplantation, 17, (Suppl. 3), S49-S54.
7. Hasford, J., Baccarani, M., Hehlmann, R., Ansari, H., Tura, S. & Zuffa, E. (1996b) Interferon-α and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-α. (Letter). Blood, 87, 5384-5391.
8. Hehlmann, R., Heimpel, H., Hasford, J., and the German CML Study Group (1995) Randomized comparison of interferon-α, hydroxyurea, and busulfan in chronic myeloid leukemia: response to Kantarjian and Talpaz and to Tura and Baccarani. Blood, 85, 3000-3002.
9. Hehlmann, R., Heimpel, H., Hasford, J., Kolb, H.J., Pralle, H., Hossfeld, D.K., Queisser, W., Löffler, H., Heinze, B., Georgii, A., Wussow, P.V., Bartram, C.R., Griesshammer, M., Bergmann, L., Essers, U., Falge, C., Hochhaus, A., Queisser, U., Sick, C., Meyer, P., Schmitz, N., Verpoort, K., Eimermacher, H., Walther, F., Westerhausen, M., Kleeberg, U.R., Heilein, A., Käbisch, A., Barz, C., Zimmermann, R., Meuret, G., Tichelli, A., Berdel, W.E., Kanz, L., Anger, B., Tigges, F.J., Schmid, L., Brockhaus, W., Zankovich, R., Schläfer, U., Weissenfels, I., Mainzer, K., Tobler, A., Perker, M., Hohnloser, J., Messerer, D., Thiele, J., Buhr, T., Ansari, H., and the German CML Study Group (1993a) Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia (CML): prolongation of survival by hydroxyurea. Blood, 82, 398-407.
10. Hehlmann, R., Heimpel, H., Hasford, J., Kolb, H.J., Pralle, H., Hossfeld, D.K., Queisser, W., Löffler, H., Hochhaus, A., Heinze, B., Georgii, A., Bartram, C.R., Griesshammer, M., Bergmann, L., Essers, U., Falge, C., Queisser, U., Meyer, P., Schmitz, N., Eimermacher, H., Walther, F., Fett, W., Kleeberg, U.R., Käbisch, A., Nerl, C., Zimmermann, R., Meuret, G., Tichelli, A., Kanz, L., Tigges, F.J., Schmid, L., Brockhaus, W., Tobler, A., Reiter, A., Perker, M., Emmerich, B., Verpoort, K., Zankovich, R., v. Wussow, P., Prümmer, O., Thiele, J., Buhr, T., Ansari, H., and the German CML Study Group (1994) Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood, 84, 4064-4077.
11. Hehlmann, R., Heimpel, H., Kolb, H.J., Heinze, B., Hochhaus, A., Griesshammer, M., Pralle, H., Queisser, W., Essers, U., Falge, C., Bergmann, L., Queisser, U., Meyer, P., Schmitz, N., Wickramanayake, P.D., Walther, F., Westerhausen, M., Kleeberg, U.R., Heilein, A., Käbisch, A., Heiss, F., Zimmermann, R., Meuret, G., Tichelli, A., Berdel, W.E., Tigges, F.J., Eimermacher, H., Schmid, L., Zankovich, R., Thiele, J., Löffler, H., Wussow, P., Buhr, T., Georgii, A., Hossfeld, D.K., Ansari, H., Hasford, J., and the German CML-Study (1993b) The German CML Study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1. Leukemia and Lymphoma, 11, (Suppl. 1), 159-168.
12. Kantarjian, H.M., Keating, M.J., Smith, T.L., Talpaz, M. & McCredie, K.B. (1990) Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. American Journal of Medicine, 88, 1-8.
13. Kantarjian, H.M., Smith, T.L., McCredie, K.B., Keating, M.J., Walters, R.S., Talpaz, M., Hester, J.P., Bligham, G., Gehan, E. & Freireich, E.J. (1985) Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood, 66, 1326-1335.
14. Kantarjian, H.M., Smith, T.L., O'Brien, S., Beran, M., Pierce, S., Talpaz, M., and the Leukemia Service (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Annals of Internal Medicine, 122, 254-261.
15. Kloke, O., Niederle, N., Qiu, J.Y., Wandl, U., Moritz, T., Nagel, H., Hiemke, M., Hawig, I., Opalka, B., Seeber, S. & Becher, R. (1993) Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia. British Journal of Haematology, 83, 399-403.
16. Mahon, F.X., Fabères, C., Montastruc, M., Si-Mour, S., Boiron, J.M., Marit, G., Bilhou-Nabera, C., Cony-Makhoul, P., Pigneux, A., Bernard, P., Broustet, A. & Reiffers, J. (1996) High response rate using recombinant alpha interferon in patients with newly diagnosed chronic myeloid leukemia. Bone Marrow Transplantation, 17, (Suppl. 3), S33-S37.
17. Ohnishi, K., Ohno, R., Tomonaga, M., Kamada, N., Onozawa, K., Kuramoto, A., Dohy, H., Mizoguchi, H., Miyawaki, S., Tsubaki, K., Miura, Y., Omine, M., Kobayashi, T., Naoe, T., Ohshima, T., Hirashima, K., Ohtake, S., Takahashi, I., Morishima, Y., Naito, K., Asou, N., Tanimoto, M., Sakuma, A., Yamada, K., and the Kouseisho Leukemia Study Group (1995) A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood, 86, 906-916.
18. Ozer, H., George, S.L., Schiffer, C.A., Rao, K., Rao, P.N., Wurster Hill, D.H., Arthur, D.D., Powell, B., Gottlieb, A., Peterson, B.A., Rai, K., Testa, J.R., LeBeau, M., Tantravahi, R. & Bloomfield, C.D. (1993) Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood, 82, 2975-2984.
19. Ross, D.W., Brunning, R.D., Kantarjian, H.M., Koeffler, P. & Ozer, H. (1993) A proposed staging system for chronic myeloid leukemia. Cancer, 71, 3788-3791.
20. Schofield, J.R., Robinson, W.A., Murphy, J.R. & Rovira, D.K. (1994) Low doses of interferon-α are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Annals of Internal Medicine, 121, 736-744.
21. Shepherd, P.C.A., Richards, S.M. & Allan, N.C. (1996) Progress with interferon in CML: results of the MRC UK CML III Study. Bone Marrow Transplantation, 17, (Suppl. 3), S15-S18.
22. Sokal, J.E., Baccarani, M., Tura, S., Fiacchini, M., Cervantes, F., Rozman, C., Gomez, G.A., Galton, D.A.G., Canellos, G.P., Braun, T.J., Clarkson, B.D., Carbonell, F., Heimpel, H., Extra, J.M., Fiere, D., Nissen, N.I., Robertson, J.E. & Cox, E.B. (1985) Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood, 66, 1352-1357.
23. Sokal, J.E., Cox, E.B., Baccarani, M., Tura, S., Gomez, G.A., Robertson, J.E., Tso, C.Y., Braun, T.J., Clarkson, B.D., Cervantes, F. & Rozman, C. (1984) Prognostic discrimination in 'good-risk' chronic granulocytic leukemia. Blood, 63, 789-799.
24. Thaler, J., Kuhr, T., Gastl, G., Huber, H., Duba, C., Kemmler, G., Gattringer, C., Fluckinger, T., Niederwieser, I., Seewann, H., Abbrederis, K., Lang, A., Gadner, H., Fereberger, W., Schiller, I., Hausmaninger, H., Weitgasser, R., Michlmayr, G., Fridrik, M. & Huber, C. (1991) Rekombinantes Interferon a-2c bei Ph-positiver chronischer myeloischer Leukaemie. Deutsche Medizinische Wochenschrift, 116, 721-728.
25. The Benelux CML Study Group (1996) Low-dose interferon-alfa 2b combined with hydroxyurea versus hydroxyurea alone for chronic myelogenous leukemia. Bone Marrow Transplantation, 17, (Suppl. 3), S19-S20.
26. + chronic myeloid leukaemia. British Journal of Haematology, 69, 463-466.
27. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New England Journal of Medicine, 330, 820-825.
28. Tura, S., Baccarani, M., Corbelli, G., and the Italian Cooperative Study Group on Chronic Myeloid Leukemia (1981) Staging of chronic myeloid leukaemia. British Journal of Haematology, 47, 105-119.